Tirzepatide vs Semaglutide for Weight Loss: First Real-World Head-to-Head Comparison
Tirzepatide produced greater weight loss than semaglutide in a real-world cohort of adults with overweight or obesity, with comparable gastrointestinal side effects.
Quick Facts
What This Study Found
Tirzepatide produced greater on-treatment weight loss than semaglutide in adults with overweight or obesity in a real-world clinical setting, with comparable gastrointestinal side effect rates.
Key Numbers
Adults with overweight or obesity identified from EHR data between May 2022 and September 2023. Both drugs were prescribed with type 2 diabetes labeling.
How They Did This
Retrospective cohort study using electronic health records from a clinical setting, comparing adults receiving tirzepatide vs. semaglutide (both labeled for type 2 diabetes).
Why This Research Matters
Patients and doctors have been waiting for head-to-head data comparing these two drugs. This real-world study provides the first large-scale direct comparison.
The Bigger Picture
Patients and doctors have been waiting for direct comparison data. Until randomized head-to-head trials are complete, this observational data provides the best available evidence for choosing between the two leading weight loss drugs.
What This Study Doesn't Tell Us
This is an observational study, not a randomized trial. Patients were not randomly assigned, so underlying differences between groups may affect results. Both drugs were prescribed for T2D, not specifically for weight loss.
Questions This Raises
- ?How much greater is tirzepatide's weight loss advantage?
- ?Would the difference change at obesity-specific doses (higher than T2D doses)?
Trust & Context
- Key Stat:
- Tirzepatide wins on weight loss In the first large real-world comparison, tirzepatide produced greater weight loss than semaglutide with comparable side effects
- Evidence Grade:
- Rated strong: large real-world cohort with electronic health record data, though observational design means patients weren't randomly assigned.
- Study Age:
- Published in 2024 using data from May 2022–September 2023. Most current real-world comparison available.
- Original Title:
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
- Published In:
- JAMA internal medicine, 184(9), 1056-1064 (2024)
- Authors:
- Rodriguez, Patricia J, Goodwin Cartwright, Brianna M, Gratzl, Samuel, Brar, Rajdeep, Baker, Charlotte, Gluckman, Ty J, Stucky, Nicholas L
- Database ID:
- RPEP-09163
Evidence Hierarchy
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
This first real-world comparison found tirzepatide produced more weight loss with similar side effects, though both are prescribed at diabetes doses here.
Do tirzepatide and semaglutide have different side effects?
Gastrointestinal side effects (nausea, diarrhea, vomiting) were comparable between the two drugs in this study.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09163APA
Rodriguez, Patricia J; Goodwin Cartwright, Brianna M; Gratzl, Samuel; Brar, Rajdeep; Baker, Charlotte; Gluckman, Ty J; Stucky, Nicholas L. (2024). Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.. JAMA internal medicine, 184(9), 1056-1064. https://doi.org/10.1001/jamainternmed.2024.2525
MLA
Rodriguez, Patricia J, et al. "Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.." JAMA internal medicine, 2024. https://doi.org/10.1001/jamainternmed.2024.2525
RethinkPeptides
RethinkPeptides Research Database. "Semaglutide vs Tirzepatide for Weight Loss in Adults With Ov..." RPEP-09163. Retrieved from https://rethinkpeptides.com/research/rodriguez-2024-semaglutide-vs-tirzepatide-for
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.